An increasing number of studies have demonstrated that EMMPRIN is associated with tumor growth, invasion and angiogenesis in many malignant cancer, such as breast carcinoma [9], hepatocellular carcinoma [10] and prostate cancer [11], by regulating the expression of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) [12]. Here, VEGFA is linked to hepatocellular carcinoma.